Research programme: cathepsin K inhibitors - GlaxoSmithKline
Alternative Names: Cathepsin K inhibitors research programme - GlaxoSmithKlineLatest Information Update: 23 Jan 2008
At a glance
- Originator GlaxoSmithKline
- Class Small molecules
- Mechanism of Action Cathepsin K inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoarthritis; Osteoporosis
Most Recent Events
- 23 Jan 2008 No development reported - Preclinical for Osteoarthritis in USA (PO)
- 23 Jan 2008 No development reported - Preclinical for Osteoporosis in USA (PO)
- 21 Sep 2005 Data presented at the 230th American Chemical Society National Meeting - (230th-ACS-2005) have been added to the pharmacokinetics and Musculosceletal disorders sections